SML3126
BI-2852
≥98% (HPLC)
别名:
(3S)-2,3-Dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-1H-isoindol-1-one, (S)-5-Hydroxy-3-(2-(((1-((1-methyl-1H-imidazol-4-yl)methyl)-1H-indol-6-yl)methylamino)methyl)-1H-indol-3-yl)isoindolin-1-one, BI 2852, BI2852
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C31H28N6O2
化学文摘社编号:
分子量:
516.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
BI-2852, ≥98% (HPLC)
InChI key
JYEQLXOWWLNVDX-PMERELPUSA-N
SMILES string
O=C1C2=C([C@H](N1)C3=C(NC4=C3C=CC=C4)CNCC5=CC6=C(C=C5)C=CN6CC7=CN(C=N7)C)C=C(C=C2)O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
BI-2852 is RAS inhibitor that binds RAS switch I and II (SI/II) pocket in both the active and inactive forms (GCP-/GDP-bound KD in μM = 0.74/2.0 (KRAS-G12D), 7.5/1.1 (KRAS), 0.57/2.5 (HRAS), 1.3/8.3 (NRAS)). BI-2852 inhibits RAS-mediated signaling and proliferation of KRAS-G12C-bearing NCI-H358 lung cancer cells (EGF-induced pERK IC50 = 5.8 μM; GI50 = 6.7 μM in soft agar with low serum) by blocking KRAS interactions with GEF SOS1 (GDP-bound G12C/G12D IC50 = 450/260 nM, GTP-bound Wt/G12C/G12D IC50 = 490/360/490 nM) and effectors CRAF (GTP-bound Wt/G12C/G12D IC50 = 1740/80/770 nM) and PI3Kα (GTP-bound Wt/G12C/G12D IC50 = 250/100/500 nM).
RAS switch I and II (SI/II) pocket-targeting inhibitor against RAS-mediated signaling and proliferation by blocking KRAS interactions with GEF and effectors.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
The small molecule BI-2852 induces a nonfunctional dimer of KRAS.
Timothy H Tran et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(7), 3363-3364 (2020-02-13)
Dirk Kessler et al.
Proceedings of the National Academy of Sciences of the United States of America, 116(32), 15823-15829 (2019-07-25)
The 3 human RAS genes, KRAS, NRAS, and HRAS, encode 4 different RAS proteins which belong to the protein family of small GTPases that function as binary molecular switches involved in cell signaling. Activating mutations in RAS are among the
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.
Dirk Kessler et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(7), 3365-3367 (2020-02-13)
Rachel Cooley et al.
Wellcome open research, 5, 20-20 (2020-06-27)
Targeting the interaction of proteins with weak binding affinities or low solubility represents a particular challenge for drug screening. The NanoLuc â ® Binary Technology (NanoBiT â ®) was originally developed to detect protein-protein interactions in live mammalian cells. Here we report
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持